Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ: ENTA · Real-Time Price · USD
11.35
+1.02 (9.87%)
At close: Oct 6, 2025, 4:00 PM EDT
11.26
-0.09 (-0.79%)
After-hours: Oct 6, 2025, 7:14 PM EDT
9.87%
Market Cap316.41M
Revenue (ttm)64.81M
Net Income (ttm)-92.01M
Shares Out 27.88M
EPS (ttm)-4.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume876,065
Open10.33
Previous Close10.33
Day's Range10.23 - 11.59
52-Week Range4.09 - 15.34
Beta0.89
AnalystsStrong Buy
Price Target20.83 (+83.52%)
Earnings DateNov 24, 2025

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2013
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ENTA
Full Company Profile

Financial Performance

In 2024, Enanta Pharmaceuticals's revenue was $67.64 million, a decrease of -14.61% compared to the previous year's $79.20 million. Losses were -$116.05 million, -13.28% less than in 2023.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for ENTA stock is "Strong Buy." The 12-month stock price target is $20.83, which is an increase of 83.52% from the latest price.

Price Target
$20.83
(83.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

4 days ago - Business Wire

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling more than 200 points on Wednesday.

Other symbols: CALM
5 days ago - Benzinga

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

6 days ago - Business Wire

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

6 days ago - Business Wire

Enanta Pharmaceuticals, Inc. - Special Call

Enanta Pharmaceuticals, Inc. - Special Call Company Participants Jennifer Viera - Executive Director of Investor Relations & Corporate Communications Jay Luly - President, CEO & Director Scott Rotting...

7 days ago - Seeking Alpha

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in  the phase 2b study. Zelicapavir demonstrated statisticall...

7 days ago - Seeking Alpha

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological...

7 days ago - Business Wire

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

10 days ago - Business Wire

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Melle...

4 weeks ago - Business Wire

Enanta Pharmaceuticals to Participate in September Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

6 weeks ago - Business Wire

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immuno...

6 weeks ago - Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunol...

2 months ago - Business Wire

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

2 months ago - Business Wire

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

2 months ago - Business Wire

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

4 months ago - Business Wire

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

4 months ago - Business Wire

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

4 months ago - Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...

5 months ago - Business Wire

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025.

6 months ago - Business Wire

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

7 months ago - Business Wire

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

7 months ago - Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

8 months ago - Business Wire

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

9 months ago - Business Wire

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indication...

10 months ago - Business Wire

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...

10 months ago - Business Wire